The largest database of trusted experimental protocols

Transit 293 reagent

Manufactured by Takara Bio
Sourced in Japan

TransIT-293 Reagent is a transfection reagent designed for efficient delivery of nucleic acids, including plasmid DNA, mRNA, and siRNA, into 293 and 293-derived cell lines. The reagent facilitates the uptake of the nucleic acids by the target cells, enabling effective gene expression or gene silencing studies.

Automatically generated - may contain errors

5 protocols using transit 293 reagent

1

Generating Feline Pit1 and Pit2 Expressing Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Feline Pit1 and Pit2 plasmids were described in a previous report (17 (link)). PLAT-A (amphotropic MuLV)-packaging cells were transfected with expression vectors (pMSCVneo-fePit1, pMSCVneo-fePit2, or pMSCVneo empty vector) using the TransIT-293 reagent (Takara, Kusatsu, Japan). Two days later, the supernatants were collected, filtered through a 0.22 µm filter, and then used to infect MDTF cells in the presence of polybrene (10 µg/mL). PLAT-GP (an env-negative)-packaging cells were co-transfected with an MuLV 10A1 env gene-expression vector, along with the pMSCVneo-fePit1, pMSCVneo-fePit2, or pMSCVneo empty vector, using the TransIT-293 reagent (Takara). Two days later, the supernatants were collected, filtered through a 0.22 µm filter, and used to infect CHO cells in the presence of polybrene (10 µg/mL). The cells were cultured in a medium containing 600 µg/mL neomycin (G418) for 2 weeks. These cells were termed MDTF-fePit1, MDTF-fePit2, MDTF-empty, CHO-fePit1, CHO-fePit2, and CHO-empty for further analyses.
+ Open protocol
+ Expand
2

Rac1 Knockdown in 3T3-L1 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The TRC2-pLKO1-puro plasmid containing shRNA for mouse Rac1 (GGAGACGGAGCTGTTGGTAAA, TRCN0000310888) and the nonmammalian shRNA control plasmid (TRC2-pLKO.5-puro non-target shRNA #1) (SHC202) were purchased from Sigma-Aldrich. Either one of these shRNA expression lentiviral plasmids was introduced into HEK-293TN cells with lentiviral packaging plasmids (pMISSION GAG POL and pMISSION VSV-G) using the TransIT-293 Reagent (Takara Bio). Forty-eight hours later, the culture medium containing lentiviruses was collected and then filter-sterilized. 3T3-L1 cells were infected with the lentiviruses at a multiplicity of infection of 4000 in the culture medium supplemented with 7 μg/mL polybrene. Those 3T3-L1 cells that stably expressed shRNA were selected with 2 μg/mL puromycin for three days.
+ Open protocol
+ Expand
3

SARS-CoV-2 Pseudovirus Infection Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Pseudovirus infection (Fig. 2E and F; Fig. S2) was performed as previously described (3 (link), 14 (link), 24 (link), 37 (link), 48 (link), 53 (link)
– (link)
56 (link)). Briefly, lentivirus (HIV-1)-based, luciferase-expressing reporter viruses were pseudotyped with SARS-CoV-2 S proteins. Lenti-X 293T cells (500,000 cells) were cotransfected with 800 ng psPAX2-IN/HiBiT (36 (link)), 800 ng pWPI-Luc2 (36 (link)), and 400 ng plasmids expressing parental S or its derivatives using TransIT-293 Reagent (Takara, Cat# MIR2700) according to the manufacturer’s protocol. Two days posttransfection, the culture supernatants were harvested and filtrated. The pseudoviruses were stored at –80°C until use. The amount of pseudoviruses prepared was quantified by the HiBiT assay using a Nano Glo HiBiT lytic detection system (Promega, Cat# N3040) as previously described (36 (link), 57 (link)). For the measurement of pseudovirus infectivity, the same amount of pseudoviruses (normalized to the HiBiT value, which indicates the amount of HIV-1 p24 antigen) was inoculated into HOS-ACE2/TMPRSS2 cells, and viral infectivity was measured as described above (see the “Neutralization assay” section).
+ Open protocol
+ Expand
4

Purification of Viral Nucleoprotein-RNA Complexes

Check if the same lab product or an alternative is used in the 5 most similar protocols
For MARV, HEK293F cells grown in 10 ml of medium (3.0 × 106 cells/ml) were transfected with 6 µg of pCAGGS-NP (1–395) using Polyethyleneimine MAX (Polysciences, Warrington, PA, USA). Three days post-transfection, the cells were collected and lysed with 0.1% Nonidet P-40 substitute (Wako, Osaka, Japan) in Tris-HCl buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA) including a cOmplete Protease Inhibitor (Roche, Basel, Switzerland) and 10 mM Ribonucleoside-Vanadyl Complex (NEB, Ipswich, MA, USA) on ice. The lysate was centrifuged at 10,000 g at 4 °C for 10 min to remove insoluble substances, and the supernatant was subjected to a discontinuous CsCl gradient ultracentrifugation at 246,100 g at 4 °C for 2 h. Then, fractions containing the NP–RNA complex were collected and ultracentrifuged at 246,100 g at 4 °C for 15 min. The pellet was suspended in Tris-HCl buffer.
For EBOV, HEK293T cells grown in 10 ml of medium (3.0 × 105 cells/ml) were transfected with 10 µg of pCAGGS-NP (1–450) using TransIT-293 Reagent (Takara, Shiga, Japan). Three days post-transfection, NP–RNA complexes were purified as described above and suspended in Tris-HCl buffer.
+ Open protocol
+ Expand
5

Recombinant Swine Interferon-Alpha Production

Check if the same lab product or an alternative is used in the 5 most similar protocols
The cDNA fragment of swIFN-α fused with a 6x-histidine tag was obtained from the transcripts of CPK cells by RT-PCR and cloned into pCAGGS.MCS (pCAGGS/swIFN-α) [39, 40] . Recombinant swIFN-α was obtained as follows: 15 µg of pCAGGS/swIFN-α was transfected into 293T cells cultured in a 100 mm dish after a 20-min incubation at room temperature with 1.5 ml of Opti-MEM I Reduced-Serum Medium and 45 µl of Trans-IT 293 Reagent (Takara Bio). After 48 h incubation at 37°C, the supernatant was collected, and swIFNα was purified using AKTA prime plus and HisTrap TM FF crude (GE Healthcare) according to the manufacturer's protocols with 400 mM imidazole for elution. The expression and bioactivity of swIFN-α were confirmed by using Western blotting and the VSV plaque inhibition test, respectively.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!